Skip to main content
Erschienen in: Drug Safety 3/2014

01.03.2014 | Original Research Article

Near-Real-Time Monitoring of New Drugs: An Application Comparing Prasugrel Versus Clopidogrel

verfasst von: Joshua J. Gagne, Jeremy A. Rassen, Niteesh K. Choudhry, Rhonda L. Bohn, Amanda R. Patrick, Gayathri Sridhar, Gregory W. Daniel, Jun Liu, Sebastian Schneeweiss

Erschienen in: Drug Safety | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Methods for near-real-time monitoring of new drugs in electronic healthcare data are needed.

Objective

In a novel application, we prospectively monitored ischemic, bleeding, and mortality outcomes among patients initiating prasugrel versus clopidogrel in routine care during the first 2 years following the approval of prasugrel.

Methods

Using the HealthCore Integrated Research Database, we conducted a prospective cohort study comparing prasugrel and clopidogrel initiators in the 6 months following the introduction of prasugrel and every 2 months thereafter. We identified patients who initiated antiplatelets within 14 days following discharge from hospitalizations for myocardial infarction (MI) or acute coronary syndrome. We matched patients using high-dimensional propensity scores (hd-PSs) and followed them for ischemic (i.e., MI and ischemic stroke) events, bleed (i.e., hemorrhagic stroke and gastrointestinal bleed) events, and all-cause mortality. For each outcome, we applied sequential alerting algorithms.

Results

We identified 1,282 eligible new users of prasugrel and 8,263 eligible new users of clopidogrel between September 2009 and August 2011. In hd-PS matched cohorts, the overall MI rate difference (RD) comparing prasugrel with clopidogrel was −23.1 (95 % confidence interval [CI] −62.8–16.7) events per 1,000 person-years and RDs were −0.5 (−12.9–11.9) and −2.8 (−13.2–7.6) for a composite bleed event outcome and death from any cause, respectively. No algorithms generated alerts for any outcomes.

Conclusions

Near-real-time monitoring was feasible and, in contrast to the key pre-marketing trial that demonstrated the efficacy of prasugrel, did not suggest that prasugrel compared with clopidogrel was associated with an increased risk of gastrointestinal and intracranial bleeding.
Literatur
1.
Zurück zum Zitat Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.PubMedCrossRef Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.PubMedCrossRef
3.
Zurück zum Zitat Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther. 2007;82:143–56.PubMedCrossRef Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther. 2007;82:143–56.PubMedCrossRef
4.
Zurück zum Zitat Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152:627–35.PubMedCrossRef Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152:627–35.PubMedCrossRef
5.
Zurück zum Zitat Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther. 2011;90:777–90.PubMedCrossRef Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther. 2011;90:777–90.PubMedCrossRef
6.
Zurück zum Zitat Resnic FS, Gross TP, Marinac-Dabic D, et al. Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices. JAMA. 2010;304:2019–27.PubMedCrossRef Resnic FS, Gross TP, Marinac-Dabic D, et al. Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices. JAMA. 2010;304:2019–27.PubMedCrossRef
7.
Zurück zum Zitat Wahl PM, Gagne JJ, Wasser TE, et al. Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples. Drug Saf. 2012;35:407–16.PubMedCrossRef Wahl PM, Gagne JJ, Wasser TE, et al. Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples. Drug Saf. 2012;35:407–16.PubMedCrossRef
8.
Zurück zum Zitat Gagne JJ, Glynn RJ, Rassen JA, et al. Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. Clin Pharmacol Ther. 2012;92:80–6.PubMedCrossRef Gagne JJ, Glynn RJ, Rassen JA, et al. Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. Clin Pharmacol Ther. 2012;92:80–6.PubMedCrossRef
9.
Zurück zum Zitat Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology. 2012;23:238–46.PubMedCentralPubMedCrossRef Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology. 2012;23:238–46.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915–20.PubMedCrossRef Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915–20.PubMedCrossRef
11.
Zurück zum Zitat Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf. 2010;19:858–68.PubMedCentralPubMedCrossRef Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf. 2010;19:858–68.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Wahl PM, Rodgers K, Schneeweiss S, et al. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf. 2010;19:596–603.PubMedCrossRef Wahl PM, Rodgers K, Schneeweiss S, et al. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf. 2010;19:596–603.PubMedCrossRef
13.
Zurück zum Zitat Tirschwell DL, Longstreth WT Jr. Validating administrative data in stroke research. Stroke. 2002;33:2465–70.PubMedCrossRef Tirschwell DL, Longstreth WT Jr. Validating administrative data in stroke research. Stroke. 2002;33:2465–70.PubMedCrossRef
14.
Zurück zum Zitat Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154:854–64.PubMedCrossRef Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154:854–64.PubMedCrossRef
15.
Zurück zum Zitat Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64:749–59.PubMedCentralPubMedCrossRef Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64:749–59.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55.CrossRef Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55.CrossRef
17.
Zurück zum Zitat Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20:512–22.PubMedCentralPubMedCrossRef Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20:512–22.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Rassen JA, Schneeweiss S. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):41–9.PubMedCrossRef Rassen JA, Schneeweiss S. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):41–9.PubMedCrossRef
19.
Zurück zum Zitat Toh S, Gagne JJ, Rassen JA, Fireman BH, Kulldorff M, Brown JS. Confounding adjustment in comparative effectiveness research conducted within distributed research networks. Med Care. 2013;51:S4–10.PubMedCrossRef Toh S, Gagne JJ, Rassen JA, Fireman BH, Kulldorff M, Brown JS. Confounding adjustment in comparative effectiveness research conducted within distributed research networks. Med Care. 2013;51:S4–10.PubMedCrossRef
20.
Zurück zum Zitat Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol. 2011;173:1404–13.PubMedCentralPubMedCrossRef Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol. 2011;173:1404–13.PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Gagne JJ, Walker AM, Glynn RJ, Rassen JA, Schneeweiss S. An event-based approach for comparing the performance of methods for prospective medical product monitoring. Pharmacoepidemiol Drug Saf. 2012;21:631–9.PubMedCentralPubMedCrossRef Gagne JJ, Walker AM, Glynn RJ, Rassen JA, Schneeweiss S. An event-based approach for comparing the performance of methods for prospective medical product monitoring. Pharmacoepidemiol Drug Saf. 2012;21:631–9.PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 273–4. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 273–4.
23.
Zurück zum Zitat Goldberg NH, Schneeweiss S, Kowal MK, Gagne JJ. Availability of comparative efficacy data at the time of drug approval in the United States. JAMA. 2011;305:1786–9.PubMedCrossRef Goldberg NH, Schneeweiss S, Kowal MK, Gagne JJ. Availability of comparative efficacy data at the time of drug approval in the United States. JAMA. 2011;305:1786–9.PubMedCrossRef
24.
Zurück zum Zitat Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297–309.PubMedCrossRef Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297–309.PubMedCrossRef
25.
Zurück zum Zitat Gagne JJ, Fireman B, Ryan PB, et al. Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):32–40.PubMedCrossRef Gagne JJ, Fireman B, Ryan PB, et al. Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):32–40.PubMedCrossRef
26.
Zurück zum Zitat Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088–97.PubMedCrossRef Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088–97.PubMedCrossRef
27.
Zurück zum Zitat Dregan A, Toschke MA, Wolfe CD, Rudd A, Ashworth M, Gulliford MC. Utility of electronic patient records in primary care for stroke secondary prevention trials. BMC Public Health. 2011;11:86.PubMedCentralPubMedCrossRef Dregan A, Toschke MA, Wolfe CD, Rudd A, Ashworth M, Gulliford MC. Utility of electronic patient records in primary care for stroke secondary prevention trials. BMC Public Health. 2011;11:86.PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Staa TP, Goldacre B, Gulliford M, et al. Pragmatic randomised trials using routine electronic health records: putting them to the test. BMJ. 2012;344:e55.PubMedCrossRef Staa TP, Goldacre B, Gulliford M, et al. Pragmatic randomised trials using routine electronic health records: putting them to the test. BMJ. 2012;344:e55.PubMedCrossRef
29.
Zurück zum Zitat Gagne JJ. You can observe a lot (about medical products) by watching (those who use them). Epidemiology. 2013;24:700–2.PubMedCrossRef Gagne JJ. You can observe a lot (about medical products) by watching (those who use them). Epidemiology. 2013;24:700–2.PubMedCrossRef
30.
Zurück zum Zitat Gagne JJ, Bykov K, Willke RJ, Kahler KH, Subedi P, Schneeweiss S. Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research. Value Health. 2013;16:1054–62.PubMedCrossRef Gagne JJ, Bykov K, Willke RJ, Kahler KH, Subedi P, Schneeweiss S. Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research. Value Health. 2013;16:1054–62.PubMedCrossRef
31.
Zurück zum Zitat Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the sentinel system—a national resource for evidence development. N Engl J Med. 2011;364:498–9.PubMedCrossRef Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the sentinel system—a national resource for evidence development. N Engl J Med. 2011;364:498–9.PubMedCrossRef
32.
Zurück zum Zitat Platt R, Carnahan RM, Brown JS, et al. The U.S. Food and Drug Administration‘s Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):1–8.PubMed Platt R, Carnahan RM, Brown JS, et al. The U.S. Food and Drug Administration‘s Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):1–8.PubMed
Metadaten
Titel
Near-Real-Time Monitoring of New Drugs: An Application Comparing Prasugrel Versus Clopidogrel
verfasst von
Joshua J. Gagne
Jeremy A. Rassen
Niteesh K. Choudhry
Rhonda L. Bohn
Amanda R. Patrick
Gayathri Sridhar
Gregory W. Daniel
Jun Liu
Sebastian Schneeweiss
Publikationsdatum
01.03.2014
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 3/2014
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-014-0136-0

Weitere Artikel der Ausgabe 3/2014

Drug Safety 3/2014 Zur Ausgabe